TiumBio Co., Ltd.

A321550

KR7321550006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
7,150 ^KRW	+0.42%		-3.77%	-26.82%

05-08	TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	CI
03-26	Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	CI

TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index

June 22, 2020 at 12:00 am

Latest news about TiumBio Co., Ltd.

TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	05-08	CI
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	03-26	CI
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer	03-11	CI
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd	12-27	CI
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd	12-19	CI
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors	23-10-22	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index	23-09-18	CI
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd	22-08-08	CI
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21-10-21	CI
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.	21-09-26	CI
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.	21-09-14	CI
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	21-09-02	CI
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding	21-08-30	CI
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	21-08-26	CI
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor	21-07-27	CI
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index	20-06-22	CI
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.	19-11-21	CI
TiumBio Co. Ltd. has filed an IPO.	19-06-24	CI

TiumBio Co., Ltd. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TIUMBIO CO., LTD.	-26.82%	137M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

TiumBio Co., Ltd.

Equities

A321550

KR7321550006

Biotechnology & Medical Research

TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index

Latest news about TiumBio Co., Ltd.

Chart TiumBio Co., Ltd.

Company Profile

Income Statement Evolution

Sector Bio Therapeutic Drugs